Intellia Therapeutics Inc. (NASDAQ: NTLA) is 10.43% higher on its value in year-to-date trading and has touched a low of $32.44 and a high of $104.87 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NTLA stock was last observed hovering at around $35.88 in the last trading session, with the day’s gains setting it 2.65% off its average median price target of $111.00 for the next 12 months. It is also 76.93% off the consensus price target high of $167.00 offered by 28 analysts, but current levels are 1.21% higher than the price target low of $39.00 for the same period.
Currently trading at $38.53, the stock is 6.69% and -6.71% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.67 million and changing 7.39% at the moment leaves the stock -25.95% off its SMA200. NTLA registered -52.74% loss for a year compared to 6-month loss of -41.15%.
The stock witnessed a 6.41% gain in the last 1 month and extending the period to 3 months gives it a -23.28%, and is 3.99% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.59% over the week and 6.07% over the month.
Intellia Therapeutics Inc. (NTLA) has around 485 employees, a market worth around $3.15B and $51.40M in sales. Distance from 52-week low is 18.79% and -63.26% from its 52-week high.
Intellia Therapeutics Inc. (NTLA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Intellia Therapeutics Inc. (NTLA) is a “Buy”. 28 analysts offering their recommendations for the stock have an average rating of 2.00, where 5 rate it as a Hold and 3 think it is a “Overweight”. 20 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Intellia Therapeutics Inc. is expected to release its quarterly report on 05/04/2023.The EPS is expected to shrink by -57.60% this year.
Intellia Therapeutics Inc. (NTLA) Top Institutional Holders
The shares outstanding are 76.05M, and float is at 75.75M with Short Float at 8.76%.
Intellia Therapeutics Inc. (NTLA) Insider Activity
A total of 14 insider transactions have happened at Intellia Therapeutics Inc. (NTLA) in the last six months, with sales accounting for 10 and purchases happening 4 times. The most recent transaction is an insider sale by Sepp-Lorenzino Laura,the company’sEVP, Chief Scientific Officer. SEC filings show that Sepp-Lorenzino Laura sold 2,330 shares of the company’s common stock on Jan 05 at a price of $38.48 per share for a total of $89659.0. Following the sale, the insider now owns 17629.0 shares.
Intellia Therapeutics Inc. disclosed in a document filed with the SEC on Jan 04 that BASTA JAMES (EVP, General Counsel) sold a total of 1,138 shares of the company’s common stock. The trade occurred on Jan 04 and was made at $37.21 per share for $42345.0. Following the transaction, the insider now directly holds 19559.0 shares of the NTLA stock.
Still, SEC filings show that on Jan 04, Sepp-Lorenzino Laura (EVP, Chief Scientific Officer) disposed off 2,508 shares at an average price of $37.21 for $93323.0. The insider now directly holds 19,959 shares of Intellia Therapeutics Inc. (NTLA).
Intellia Therapeutics Inc. (NTLA): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -56.47% down over the past 12 months.